Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

Chronic Hepatitis Clinical Trial

— ELAD  

Official title:

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) in Patients With Acute on Chronic Hepatitis (AOCH)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00771446
• Other study ID #: VTI-201
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 9, 2008
• Last updated: April 5, 2013
• Start date: October 2008
• Est. completion date: April 2009

Study information

• Verified date: April 2013
• Source: Vital Therapies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Evaluate on how well the ELAD system works in treating people with liver failure.

Description:

This is a multicenter, open-label, randomized, concurrent control study of subjects with acute on chronic hepatitis. Subjects meeting the eligibility requirements of the study will be randomly assigned in a 2:1 ratio to receive either standard medical therapy for acute liver failure plus the ELAD system, or standard medical therapy alone, with the latter defined as conventional therapy for acute on chronic hepatitis determined to be clinically appropriate by the treating physician.

Immediately prior to treatment initiation, subject eligibility will be confirmed. Treatment with ELAD will continue for a minimum of 3 days and up to a maximum of 10 days or until clinical status improves relative to study entry. Subjects will be followed until 30 days has elapsed since study enrollment (control) or 30 days has elapsed since cessation of ELAD therapy (ELAD group), whichever comes first.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: April 2009
• Est. primary completion date: April 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 69 Years

Eligibility

Inclusion Criteria:

1. Weight >40 kilograms

2. Age >18 and <70 years

3. Acute decompensation of cirrhosis over the preceding 48-72 hour period

4. Up to 4 weeks from symptom onset to presentation

5. Presence of a precipitating event

6. Either a MELD score of =32, or =24 with one or more of the following

• Severe encephalopathy of grade 3 or 4 on the Westhaven scale

• Renal dysfunction typical of type-1 hepato-renal syndrome, i.e. acute renal failure without evidence of elevated serum creatinine (>2.5mg/dL) during the 1 to 6 months prior to study entry. Serum creatinine at study entry >2.5mg/dL does not exclude the subject from enrolment

7. SOFA score =9 at the initial Screening Visit

Exclusion Criteria:

1. Platelets <50,000 or reducing to <80,000 over a 72 hour period

2. Renal failure: Serum creatinine =2.5 mg/dL as measured during the 1 - 6 month period prior to study entry. If a subject has a contraindication to renal replacement therapy (hemodialysis or hemofiltration), then the subject should be excluded from entry into the study

3. Active sepsis. Sepsis will be defined as positive microbiological culture, ascitic white cell count >450 cells/mm³ (or ascitic neutrophil count >250 cells/mm³), or clinical signs and chest x-ray appearances for at least 48 hours without clinical improvement prior to randomization, or other evidence of infection not under control

4. Evidence of major hemorrhage indicated by requiring = 4 unit blood transfusion within a 24 hour period, or hemodynamic instability (sustained pulse >120 beats/min and systolic blood pressure <100 mmHg over one hour). Subjects with a recent history of gastrointestinal hemorrhage who have been successfully treated and remain hemodynamically stable for a period of 48 hours will then be eligible for the study

5. Evidence (by physical exam, history, or laboratory evaluation) of significant concomitant disease including chronic congestive heart failure, vascular disease, emphysema, AIDS, fatty-liver disease of non-alcoholic origin, hepatitis due to herpes virus, Wilson's disease, or Budd-Chiari syndrome;

6. Known history of hepatocellular carcinoma beyond the Milan criteria and/or portal vein thrombosis

7. Evidence of Small Bowel Perforation within 48 hours of treatment;

8. Evidence of brain death as determined by blood flow studies positive for herniation and/or absence of pupillary reflex

9. Mean Arterial Pressures (MAP) < 50 mm Hg for one hour or longer;

10. Requirement for escalating doses of vasopressor support of an alpha-adrenergic agent for one hour or longer and evidence of hemodynamic instability;

11. Clinical or radiographic evidence of a new stroke or intracerebral bleeding

12. Seizures uncontrolled by medication

13. Acute myocardial infarction based on clinical and/or electrocardiographic evidence

14. Lung disease defined by a PaO2 <60 mm Hg or a history of severe COPD or interstitial lung disease

15. Pregnancy as determined by ßHCG results, or lactation

16. Participation in another investigational drug, biologic, or device study within one month of enrollment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Hepatitis
• Chronic Hepatitis
• Hepatitis
• Hepatitis A
• Hepatitis, Chronic

Intervention

Biological:
• ELAD plus standard of care treatment
ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Other:
• Standard of care treatment
Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Locations

Country	Name	City	State
United States	University of Michigan Hospital	Ann Arbor	Michigan
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Chicago Medical Center	Chicago	Illinois
United States	Scripps Clinic	La Jolla	California
United States	Columbia University Medical Center	New York	New York
United States	California Pacific Medical Center	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Vital Therapies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To provide evidence that (1) subjects treated with ELAD have a higher 30-day transplant-free survival in subjects with AOCH than those not treated with ELAD, and (2) it is safe when used for 3 to 10 days of treatment.		12 months	Yes